John Newman, an analyst from Canaccord Genuity, maintained the Buy rating on BioNTech SE (BNTX – Research Report). The associated price ...
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Voyager Therapeutics (VYGR – Research ...
Zacks.com on MSN2h
BNTX to Boost Oncology Pipeline With Biotheus Acquisition, Stock UpBioNTech SE BNTX announced that it has entered into a definitive agreement to acquire China-based biotech, Biotheus, to ...
The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...
BioNTech, the German developer of a widely used mRNA vaccine for the coronavirus, agreed to pay US$800 million (HK$6.24 ...
BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...
BioNTech is shelling out $800 million upfront to acquire China-based Biotheus in a move that would give it access to a ...
On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...
BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...
BioNTech (NASDAQ:BNTX) said it has agreed to buy bispecific antibody developer Biotheus for up to $950M, including $150M in potential milestone payments. Under the deal, BioNTech (BNTX) will pay $800M ...
German drugmaker to use state-of-art antibody in tandem with advanced therapies to more effectively fight cancer, detect ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback